Physician profile
Mark R Benfield
NPI 1811004245
$234,409.34
in general payments reported to CMS, 2019-2025
7 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $24K · 2021: $22K · 2022: $26K · 2023: $51K · 2024: $43K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Honoraria: $40K · Travel and Lodging: $15K · Consulting Fee: $14K · Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,762.50 |
| Honoraria | $39,912.00 |
| Travel and Lodging | $14,775.49 |
| Consulting Fee | $13,696.63 |
| Food and Beverage | $1,533.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $150,758.77 | 2019-2023 | Procysbi |
| Amgen INC. | $76,058.16 | 2024-2025 | Procysbi |
| Mallinckrodt Enterprises LLC | $7,341.17 | 2019 | |
| Leadiant Biosciences, INC. | $212.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.24 | 2020 | |
| Travere Therapeutics, INC. | $15.00 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Benfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.